Bioavailability of Four Different Pharmaceutical Preparations of Carbamazepine

Abstract

The bioavailabilities of 2 tablet brands of carbamazepine (CBZ) (Tegretol, A; Neurotol, B) were compared with 2 new experimental preparations (C, D) in humans. Formulation A showed a more sustained release nature than did the other formulations. The AUC0 .fwdarw. .infin. gave no significant differences between treatment A and 3 other treatments. If AUC0 .fwdarw. 72 was calculated instead of AUC0 .fwdarw. .infin., the preparation A gave the significantly lower bioavailability than the other compounds. Formulations A and B are marketed as generically equivalent preparations in Finland. Their pharmacokinetic parameters after a single dose were different.